Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Editorial Policies
    • Open Access
  • Content
    • Current Issue
    • Online First
    • Archive
    • Topic/Program Collections
    • Blog
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Editorial Policies
    • Open Access
  • Content
    • Current Issue
    • Online First
    • Archive
    • Topic/Program Collections
    • Blog
  • Subscribe
  • Alerts
  • Careers
American Academy of Pediatrics
Research Articles

Impact of a Prospective Audit and Feedback Antimicrobial Stewardship Program in Pediatric Units in Tertiary Care Teaching Hospital in Thailand

Sineenart Chautrakarn, Suvaporn Anugulruengkitt, Thanyawee Puthanakit, Thanapoom Rattananupong and Narin Hiransuthikul
Hospital Pediatrics November 2019, 9 (11) 851-858; DOI: https://doi.org/10.1542/hpeds.2019-0027
Sineenart Chautrakarn
aPreventive and Social Medicine, Faculty of Medicine and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suvaporn Anugulruengkitt
bDivision of Pediatric Infectious Diseases, Departments of Pediatrics and
cCenter of Excellence for Pediatric Infectious Diseases and Vaccines, Chulalongkorn University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thanyawee Puthanakit
bDivision of Pediatric Infectious Diseases, Departments of Pediatrics and
cCenter of Excellence for Pediatric Infectious Diseases and Vaccines, Chulalongkorn University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thanapoom Rattananupong
aPreventive and Social Medicine, Faculty of Medicine and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Narin Hiransuthikul
aPreventive and Social Medicine, Faculty of Medicine and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments
Loading
Download PDF

Abstract

BACKGROUND: Antimicrobial stewardship programs (ASPs) have been proven to be beneficial in reducing the use of antimicrobial agents, antibiotic resistance, and health care costs. The data supporting the utility of ASPs has come largely from adult hospital units, but few pediatric hospital units have implemented ASPs. Our objective for this study was to assess the impact of ASPs in pediatric units in tertiary care teaching hospitals.

METHODS: We conducted a retrospective chart review to compare antimicrobial use pre- and post-ASP over a 6-month period in a tertiary care hospital in which an ASP had been in use since July 2017. Meropenem, vancomycin, and colistin were selected to be monitored. ASP rounds were conducted twice a week to assess and provide feedback on antimicrobial prescriptions. Antimicrobial use was measured as days of therapy (DOTs) per 1000 patient-days and was compared pre- and post-ASP by using independent t tests.

RESULTS: Charts of children hospitalized who were in antimicrobial treatment pre-ASP (44.3%) and post-ASP (41.7%) were reviewed. The percentages of children who received selected antimicrobial agents did not differ between pre- and post-ASP. During the post-ASP period, a significant reduction in DOT with vancomycin and colistin was observed. Vancomycin use decreased from 58.5 to 40.2 DOTs per 1000 patient-days (P = .038), and colistin decreased from 36.3 to 13.8 DOTs per 1000 patient-days (P = .026). Meropenem use decreased from 126.8 to 111.2 DOTs per 1000 patient-days (P = .467). Between the 2 periods, there was no effect on length of stay and mortality.

CONCLUSIONS: ASPs can lead to a significant reduction in selected antimicrobial use in children who are hospitalized, with no effect on length of stay or mortality rate.

Antimicrobial resistance is 1 of the greatest public health threats worldwide.1 Infections from antimicrobial-resistant bacteria and Clostridium difficile lead to increased morbidity and mortality, longer hospital stays, and dramatically increased health care costs.2,3 The Centers for Disease Control and Prevention estimates that drug-resistant bacteria cause 2 million illnesses and ∼23 000 deaths each year in the United States.4 In the European Union, ∼25 000 patients die of infections caused by the selected multidrug-resistant bacteria each year.5 In Thailand, antimicrobial-resistance infections resulted in at least 3.24 million days of hospitalization and 38 481 deaths.6 Overuse and inappropriate use of antibiotics are important factors that lead to worldwide antibiotic resistance.7,8 Data from pediatric studies have revealed that 37% to 60% of children will receive at least 1 antimicrobial during hospitalization.9–11 Furthermore, up to 35% of inpatient antibiotic prescriptions are either unnecessary or inappropriate.12–14

In 2007, the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America published guidelines on the development of antimicrobial stewardship programs (ASPs) within health care institutions.15 In 2014, the Centers for Disease Control and Prevention developed ASP guidance to assist hospitals in either starting or expanding programs to improve antibiotic prescribing and suggested that hospitals should have institute ASPs.16 The primary purpose for ASPs is to optimize clinical outcomes while minimizing the unintended consequences of antimicrobial use, including toxicity, the selection of pathogenic organisms (such as C difficile), and antibiotic resistance.8,17

ASPs have proven beneficial in reducing the frequency and duration of target drug prescribing, the occurrence of C difficile–associated diseases, and health care costs.18 Although data supporting the utility of ASPs have come largely from adult units, few pediatric units have implemented comprehensive ASPs.19,20 Recent studies have revealed that the successful implementation of antimicrobial stewardship strategies has had a significant impact on reducing selected and nonselected antimicrobial use, thus improving the quality of care of children who are hospitalized and preventing antibiotic resistance.21–25

In Asia, many countries have implemented ASPs for children who are hospitalized, including Japan,26 Singapore,27,28 and China.29

In Thailand, previous research has revealed that the utility of ASPs has come largely from medical schools,30 but there has been a lack of evidence regarding the impact of ASP implementation, particularly in pediatric units. The study hospital was a tertiary care teaching hospital in Bangkok, Thailand, with a 200-bed pediatric unit. The ASP was fully implemented in the pediatric unit in July 2017. To address the limitations in the existing evidence regarding the impact of pediatric ASPs, our main objective was to describe the structure, function, and clinical impact of a pediatric ASP on antimicrobial use and patient outcomes at the tertiary care teaching hospital in Thailand and to provide an interim analysis after the ASP had been fully implemented for a 6-month period.

Methods

ASP

The strategy for ASPs has been to use the “prospective audit and feedback” approach.31 Since the program’s inception in July 2017, its membership has included infectious disease (ID) pediatricians and pharmacists with ID training. The ASP team selected the antimicrobial agents (meropenem, vancomycin, and colistin) to be monitored in terms of their use and appropriateness of treatment. These agents were selected because meropenem is a broad-spectrum antimicrobial agent most commonly used in the hospital, vancomycin is an antimicrobial agent used for multidrug-resistant Gram-positive bacterial infections, and colistin is an agent used for multidrug-resistant Gram-negative bacterial infections. The goals for the ASP were to (1) decrease use of the selected antimicrobial agents; (2) facilitate the early de-escalation or discontinuation of the selected antimicrobial agents’ empirical regimens, guided by the microbiologic results; (3) ensure dosing accuracy; and (4) improve patient safety and avoid drug errors. The ASP team developed practice guidelines (Supplemental Tables 3 and 4) and implemented prospective day 3 audits of the selected antimicrobial agents with education and feedback. Practice guidelines of appropriate indications and dosage of the selected antimicrobial agents were developed and distributed to physicians during the annual conference held for health care providers working in the pediatric unit of the hospital.

Regarding the process of prospective audit and feedback, the ASP team received a list of all active selected antimicrobial orders generated every morning by the pharmacist team. The ASP ward rounds were conducted twice a week on Monday and Thursday. For example, if a child starts antimicrobial agents on Sunday, the first assessment of indication and dosage would be performed during the ASP rounds on Monday. On Thursday, the second assessment would be conducted, with feedback to the primary team. Therefore, the duration of antimicrobial treatment might vary from 3 to 6 days from the primary to the secondary assessment. All assessments on selected antimicrobial use and recommendations given were recorded in the drug use evaluation (DUE) form (Fig 1). Acceptance of the recommendations was checked within 72 hours after the recommendations were made during regular ward rounds by the pediatric ID physicians.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

DUE form. CNS, central nervous system; CSF, cerebrospinal fluid; NA, not applicable.

Setting and Study Design

The study was conducted at a tertiary care teaching hospital in Bangkok, Thailand. Thirteen pediatric units, including 9 general unit, 1 oncology unit, 2 PICUs, and 1 surgical unit, were included, with a total of 200 beds and ∼500 admissions per month. Electronic medical records and a computerized information system relating to the antibiotics dispensed to the patients were not available at the time of the study.

We conducted a retrospective chart review using data from patients who were discharged from the hospital between November 2016 and April 2017 (pre-ASP period) and between July 2017 and December 2017 (post-ASP period) and received ≥1 antimicrobial agent of interest to this study. We excluded May 2017 and June 2017 from the study because the program was launched during this period. Our goal for the study was to assess the impact of an ASP on selected antimicrobial use, hospital length of stay (LOS), and number of deaths, comparing pre- and post-ASP periods.

Data Collection

Medical records of all patients who were discharged from the hospital during these periods were reviewed. A data set from all patients who received antimicrobial therapy was prepared and included the following: demographic parameters (age and sex), antimicrobial(s) prescribed, route of administration, duration of antimicrobial use, clinical indication, patient admission day(s), and patient outcome at discharge. Medical records that could not be obtained for review were excluded from the analysis (Fig 2). Total patient-days were calculated for all patients who were discharged from the hospital during the study periods, and ASP recommendations and acceptance were tracked by using data collected from the DUE form, which was used to evaluate and record recommendations given during ASP ward rounds.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Patient groups for pre- and post-ASP analysis.

Measures of Antimicrobial Use

To evaluate trends in antimicrobial consumption, we used days of therapy (DOTs) per 1000 patient-days as the metric.32 DOTs are calculated as the aggregate sum of antimicrobial agents used per patient per day. For example, a child given meropenem daily for 2 days for any dosage given would result in a total of 2 DOTs.

The term “all antimicrobials” refers to any antimicrobial with intravenous, oral, or intramuscular routes of administration and excludes topical antimicrobial agents, systemic antifungal agents, and antiviral agents. In this study, we also examined a subset of selected antimicrobial agents, including intravenous meropenem, vancomycin, and colistin. To ensure that a decrease in the use of the selected antimicrobial agents had no effect on increasing the use of other antimicrobial agents, nonselected antimicrobial agents, including intravenous third-generation cephalosporins (cefotaxime, ceftriaxone, and ceftazidime), piperacillin/tazobactam, ampicillin/sulbactam, cefoperazone/sulbactam, and levofloxacin, were also included in the study.

Statistical Analysis

The average antimicrobial use rates (measured as DOTs per 1000 patient-days for selected and nonselected antimicrobial agents) pre- and post-ASP were compared by using independent t tests. The duration of each selected and nonselected antimicrobial therapy and LOS during the pre- and post-ASP periods were compared by using the Mann–Whitney U test. In-hospital mortality during the pre- and post-ASP periods was compared by using the χ2 test. All statistical analyses were estimated by using SPSS version 22 (IBM SPSS Statistics, IBM Corporation, Armonk, NY).

Results

Study Population and Demographic Data

A total of 1055 patients receiving antimicrobial treatment were enrolled during the pre-ASP period. During the post-ASP period, 1184 patients were enrolled. Overall, no statistically significant differences in the demographic data were observed between the 2 study groups (Table 1).

View this table:
  • View inline
  • View popup
TABLE 1

Comparison of Patient Groups in the Pre- and Post-ASP Periods

ASP Recommendations and Acceptance

During the 6-month post-ASP period, a total of 241 selected antimicrobial treatments were reviewed, and the ASP team made 170 recommendations on the selected antimicrobial agents in cases of inappropriate use. Discontinuation of the selected antimicrobial agents was the most common recommendation (51.2%), followed by de-escalation (38.6%) and dose adjustment (10.2%). The most accepted recommendation was dose adjustment (85.7%), followed by de-escalation (47.9%) and discontinuation (21.5%). The overall acceptance of the recommendations was 43.5%.

Selected Antimicrobial Use

After ASP implementation, the percentage of hospitalized children receiving selected antimicrobial agents (meropenem, vancomycin, and colistin) did not significantly change (16.0% and 14.7% [P = .368], 8.5% and 6.4% [P = .057], and 4.1% and 2.8% [P = .093], respectively). However, consumption of vancomycin and colistin significantly decreased during the post-ASP period. DOTs per 1000 patient-days with vancomycin decreased by 31.3%, from 58.5 to 40.2 (P = .038), whereas DOTs per 1000 patient-days with colistin decreased by 61.9%, from 36.3 to 13.8 (P = .026). DOTs per 1000 patient-days with meropenem revealed a reduction trend of 12.3%, from 126.8 to 111.2, but no statistically significant difference (P = .467) (Fig 3). The median duration of colistin prescriptions, but not meropenem or vancomycin prescriptions, decreased during the post-ASP period (Table 2).

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Comparison of average selected antimicrobial and nonselected antimicrobial use as DOTs per 1000 patient-days during the pre- and post-ASP periods. * P < 0.05.

View this table:
  • View inline
  • View popup
TABLE 2

Comparison of Selected Antimicrobial Use During Pre- and Post-ASP Periods

Nonselected Antimicrobial Use

During the post-ASP period, the percentage of hospitalized children receiving ceftriaxone and/or cefotaxime was 43.1%, the percentage of hospitalized children receiving piperacillin/tazobactam was 14.1%, the percentage of hospitalized children receiving ampicillin/sulbactam was 1.1%, and the percentage of hospitalized children receiving levofloxacin was 1.8%. These figures were not significantly different from those obtained during the pre-ASP period. In contrast, the percentage of ceftazidime prescriptions increased from 9.4% (pre-ASP period) to 12.6% (post-ASP period) (P = .014), whereas the percentage of cefoperazone/sulbactam prescriptions, a third-generation cephalosporin/β-lactamase inhibitor combination with anti-Pseudomonas activity, decreased from 2.6% to 1.1% (P = .009). The consumption of cefoperazone/sulbactam and levofloxacin decreased from 22.8 to 5.9 DOTs per 1000 patient-days (−74.3%, P = .005) and from 14.6 to 7.6 DOTs per 1000 patient-days (−48.0%; P = .013), respectively. No significant differences between the 2 periods for other nonselected antimicrobial agents were observed on the DOT (Fig 3).

LOS and In-Hospital Mortality

The median LOS of all patients in the pre-ASP period was 7 days (interquartile range [IQR], 3–15), and in the post-ASP period, it was also 7 days (IQR, 3–14); thus, there was no significant difference (P = .750). For patients who received selected antimicrobial treatment, the median LOS in the pre-ASP period was 27 days (IQR, 15–49), and during the post-ASP period, it was 24 days (IQR, 15–41), with no significant difference (P = .114). There was also no significant difference regarding in-hospital mortality among patients who received selected antimicrobial treatment during the pre- and post-ASP periods (15 of 190 deaths [7.9%] and 13 of 196 deaths [6.6%]; P = .633).

Discussion

To our knowledge, in this study, we are the first to evaluate the prospective audit and feedback of ASPs in a pediatric tertiary care setting in Thailand after implementation of the program for a 6-month period. This study reveals that this type of ASP strategy can successfully reduce the frequency of use and DOTs for selected antimicrobial agents in children who are hospitalized, with no change in the increase of the use of nonselected antimicrobial agents. Furthermore, in the study, we provide insight into antimicrobial agents, patient outcomes, types of ASP recommendations, and acceptance that a prospective audit and feedback ASP in a tertiary care setting will encounter.

Our findings align with those of previous reports of ASP effectiveness from various settings in other countries. In recent studies, including 1 by Newland et al,25 authors have studied the impact of ASPs at 25 children’s hospitals in the United States. They demonstrated that prospective audit and feedback had a significant impact on decreasing the use of selected antibiotics monitored by ASPs at children’s hospitals.25 Kreitmeyr et al33 studied the impact of ASPs on broad-spectrum antibiotic use in general pediatric wards in Germany. The results also revealed that the same ASP strategy decreased antimicrobial use in children who were hospitalized.33 In addition, Willis et al34 and Klatte et al35 studied the impact of a prospective audit with feedback on antimicrobial use. Both studies revealed that the use of antimicrobial agents decreased.

Although our intervention (prospective audit and feedback) has been focused on providing feedback on the use of selected antimicrobial agents during regular ASP ward rounds, the clinical guidelines employed by the ASP might also contribute to improving antimicrobial use before prescribing decisions are made.23 This might reduce the selected antimicrobial use as an empirical therapy. However, the results of this study revealed that the use of meropenem remained unchanged. The DOTs tended to decrease post-ASP but not significantly. This finding revealed an area in which improvements could be made regarding the use of meropenem, and the ASP team should investigate the cause; otherwise, other interventions should be initiated.

For nonselected antimicrobial agents, the results revealed that there were no significant differences in DOTs between the 2 periods. There could be several potential reasons the DOTs of nonselected antimicrobial agents did not change. These reasons include the fact that most recommendations were for discontinuation and not change of agent, that therapy was continued for at least 72 hours before any ASP intervention (by which time the culture results or clinical evidence would have confirmed the absence of infection and the possibility of the antimicrobial being stopped), or that microbiologic test results confirmed initial therapy as the appropriate choice. These findings also reveal that there is room for improving interventions by the ASP team through further implementation and research. Regarding the reasons for changing the consumption of nonselected antimicrobial agents, we need microbiologic data that can be used to explain the variability results, but such data were not included in this study. There were no shortages of antimicrobial agents in the study hospital during the study periods.

Although we can significantly decrease broad-spectrum antimicrobial use in the hospital, ASP-recommendation acceptance rates appear low in this study (43.5%). However, a greater acceptance rate can be obtained by providing education regarding the benefit of ASPs, by encouraging corroboration in ASP implementation among health care providers, and by identifying the barriers related to ASP-recommendation refusal among pediatricians. For example, a recent study in a pediatric setting in the United States revealed that barriers related to stewardship programs included the need to educate incoming housestaff and other new recruits on a routine basis and to find mechanisms to change long-standing antimicrobial prescribing practices. Both barriers likely require significant education efforts.36

The additional metrics of implementing ASP measurement, including improved patient clinical outcomes in terms of LOS and mortality, are also important.37 The results of this study revealed that ASP could reduce the use of selected broad-spectrum antimicrobial agents without changing the LOS or mortality rate. The long-term effects of ASPs on patients’ clinical outcomes must be further investigated. Recent studies, including a study by Lee et al,38 revealed that the average LOS during the pre- and postimplementation years was 6 and 6.13 days, respectively. There was no difference in the rate of discharge from the critical care units due to death during the preimplementation period versus the postimplementation period.38 Similarly, a study by Turner et al39 over a 2-year postintervention period revealed that LOS and mortality rates were unchanged.

There were several limitations to this study. We did not evaluate the severity of the patients’ conditions. The pre- and post-ASP periods were <1 year given that antimicrobial use might have depended on the seasonality of pediatric illnesses. However, the demographic data that we collected of the study population revealed that the 2 study groups were similar. We also did not collect the culture results of patients, which might be associated with the use of selected antimicrobial agents. The objective for this study was not linked to resistance data, which might have benefited from successful ASP evaluation. In addition, there were no data regarding compliance with institutional antimicrobial prescribing guidelines before ASP implementation to compare the pre- and post-ASP periods, which might be a better metric for judicious antimicrobial use instead of simply consumption because this data could also be another success point of the program’s effort. Observed changes in this study could be due to the differences in the patient case mix during the observation periods that were not tracked in the study. Lastly, because we could not access an individual patient’s antimicrobial cost, we did not evaluate the true cost of antimicrobial agents. Consequently, an ASP cost-benefit analysis was not conducted in this study.

Conclusions

A prospective audit and feedback ASP can lead to a significant reduction in selected antimicrobial use among children who are hospitalized. The median LOS and in-hospital mortality rate were similar pre- and post-ASP. The study ASP has been in effect for 6 months, which is a short observation period. We aim to continue to measure the sustained impact of the program over time.

Acknowledgments

We thank all staff at the Center of Excellence for Pediatric Infectious Diseases and Vaccines, Chulalongkorn University for all support.

Footnotes

  • FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

  • FUNDING: Supported by the 90th anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund; grant 37, 4/2560).

  • POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

References

  1. ↵
    Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed July 18, 2016
  2. ↵
    1. Roberts RR,
    2. Hota B,
    3. Ahmad I,
    4. et al
    . Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49(8):1175–1184
    OpenUrlCrossRefPubMed
  3. ↵
    1. Livermore DM
    . Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012;27(2):128–142
    OpenUrlCrossRefPubMed
  4. ↵
    Centers for Disease Control and Prevention. National action plan for combating antibiotic-resistant bacteria. 2015. Available at: https://www.cdc.gov/drugresistance/pdf/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf. Accessed July 18, 2016
  5. ↵
    European Center for Disease Prevention and Control; European Medicine Agency. Technical report: the bacterial challenge: time to react. 2009. Available at: http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf. Accessed July 18, 2016
  6. ↵
    1. Pumart P,
    2. Phodha T,
    3. Thamlikitkul V,
    4. Riewpaiboon A,
    5. Prakongsai P,
    6. Limwattananon S
    . Health and economic impacts of antimicrobial resistant infections in Thailand: a preliminary study. Journal of Health Services Research and Policy. 2012;6(3):352–360
    OpenUrl
  7. ↵
    1. Watkins RR,
    2. Bonomo RA
    . Overview: global and local impact of antibiotic resistance. Infect Dis Clin North Am. 2016;30(2):313–322
    OpenUrlCrossRefPubMed
  8. ↵
    1. Holloway K,
    2. van Dijk L
    . The World Medicines Situation 2011: Rational Use of Medicines. 3rd ed. Geneva, Switzerland: World Health Organization; 2011. Available at: www.who.int/medicines/areas/policy/world_medicines_situation/WMS_ch14_wRational.pdf. Accessed July 18, 2016
  9. ↵
    1. Gerber JS,
    2. Newland JG,
    3. Coffin SE,
    4. et al
    . Variability in antibiotic use at children’s hospitals. Pediatrics. 2010;126(6):1067–1073
    OpenUrlAbstract/FREE Full Text
    1. Levy ER,
    2. Swami S,
    3. Dubois SG,
    4. Wendt R,
    5. Banerjee R
    . Rates and appropriateness of antimicrobial prescribing at an academic children’s hospital, 2007-2010. Infect Control Hosp Epidemiol. 2012;33(4):346–353
    OpenUrlCrossRefPubMed
  10. ↵
    1. Versporten A,
    2. Bielicki J,
    3. Drapier N,
    4. Sharland M,
    5. Goossens H
    ; ARPEC Project Group. The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children. J Antimicrob Chemother. 2016;71(4):1106–1117
    OpenUrlCrossRefPubMed
  11. ↵
    1. Bolon MK,
    2. Arnold AD,
    3. Feldman HA,
    4. et al
    . Evaluating vancomycin use at a pediatric hospital: new approaches and insights. Infect Control Hosp Epidemiol. 2005;26(1):47–55
    OpenUrlCrossRefPubMed
    1. Hecker MT,
    2. Aron DC,
    3. Patel NP,
    4. Lehmann MK,
    5. Donskey CJ
    . Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med. 2003;163(8):972–978
    OpenUrlCrossRefPubMed
  12. ↵
    1. Patel SJ,
    2. Oshodi A,
    3. Prasad P,
    4. et al
    . Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance. Pediatr Infect Dis J. 2009;28(12):1047–1051
    OpenUrlCrossRefPubMed
  13. ↵
    1. Dellit TH,
    2. Owens RC,
    3. McGowan JE Jr.,
    4. et al
    ; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–177
    OpenUrlCrossRefPubMed
  14. ↵
    1. Fridkin S,
    2. Baggs J,
    3. Fagan R,
    4. et al
    ; Centers for Disease Control and Prevention (CDC). Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep. 2014;63(9):194–200
    OpenUrlPubMed
  15. ↵
    1. Goff DA,
    2. File TM Jr.
    . The evolving role of antimicrobial stewardship in management of multidrug resistant infections. Infect Dis Clin North Am. 2016;30(2):539–551
    OpenUrl
  16. ↵
    1. File TM Jr.,
    2. Srinivasan A,
    3. Bartlett JG
    . Antimicrobial stewardship: importance for patient and public health. Clin Infect Dis. 2014;59(suppl 3):S93–S96
    OpenUrlCrossRefPubMed
  17. ↵
    1. Newland JG,
    2. Banerjee R,
    3. Gerber JS,
    4. Hersh AL,
    5. Steinke L,
    6. Weissman SJ
    . Antimicrobial stewardship in pediatric care: strategies and future directions. Pharmacotherapy. 2012;32(8):735–743
    OpenUrlCrossRefPubMed
  18. ↵
    1. Newland JG,
    2. Gerber JS,
    3. Weissman SJ,
    4. et al
    . Prevalence and characteristics of antimicrobial stewardship programs at freestanding children’s hospitals in the United States. Infect Control Hosp Epidemiol. 2014;35(3):265–271
    OpenUrlCrossRefPubMed
  19. ↵
    1. Di Pentima MC,
    2. Chan S
    . Impact of antimicrobial stewardship program on vancomycin use in a pediatric teaching hospital. Pediatr Infect Dis J. 2010;29(8):707–711
    OpenUrlCrossRefPubMed
    1. Di Pentima MC,
    2. Chan S,
    3. Hossain J
    . Benefits of a pediatric antimicrobial stewardship program at a children’s hospital. Pediatrics. 2011;128(6):1062–1070
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Metjian TA,
    2. Prasad PA,
    3. Kogon A,
    4. Coffin SE,
    5. Zaoutis TE
    . Evaluation of an antimicrobial stewardship program at a pediatric teaching hospital. Pediatr Infect Dis J. 2008;27(2):106–111
    OpenUrlPubMed
    1. Hersh AL,
    2. De Lurgio SA,
    3. Thurm C,
    4. et al
    . Antimicrobial stewardship programs in freestanding children’s hospitals. Pediatrics. 2015;135(1):33–39
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Newland JG,
    2. Stach LM,
    3. De Lurgio SA,
    4. et al
    . Impact of a prospective-audit-with-feedback antimicrobial stewardship program at a children’s hospital. J Pediatric Infect Dis Soc. 2012;1(3):179–186
    OpenUrlCrossRefPubMed
  22. ↵
    1. Aizawa Y,
    2. Suwa J,
    3. Higuchi H,
    4. et al
    . Antimicrobial stewardship program in a pediatric intensive care unit. J Pediatric Infect Dis Soc. 2018;7(3):e156–e159
    OpenUrl
  23. ↵
    1. Seah VXF,
    2. Ong RYL,
    3. Lim ASY,
    4. Chong CY,
    5. Tan NWH,
    6. Thoon KC
    . Impact of a carbapenem antimicrobial stewardship program on patient outcomes. Antimicrob Agents Chemother. 2017;61(9):e00736-17
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Seah XF,
    2. Ong YL,
    3. Tan SW,
    4. et al
    . Impact of an antimicrobial stewardship program on the use of carbapenems in a tertiary women’s and children’s hospital, Singapore. Pharmacotherapy. 2014;34(11):1141–1150
    OpenUrl
  25. ↵
    1. Zhang ZG,
    2. Chen F,
    3. Chen JZ
    . Introducing an antibiotic stewardship program in a pediatric center in China. World J Pediatr. 2018;14(3):274–279
    OpenUrl
  26. ↵
    1. Khawcharoenporn T,
    2. Apisarnthanarak A,
    3. Mundy LM
    . National survey of antimicrobial stewardship programs in Thailand. Am J Infect Control. 2013;41(1):86–88
    OpenUrl
  27. ↵
    Center for Disease Control and Prevention. The core elements of hospital antibiotic stewardship programs. 2014. Available at: www.cdc.gov/antibiotic-use/healthcare/pdfs/core-elements.pdf. Accessed July 18, 2016
  28. ↵
    WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2012. Available at: https://www.whocc.no/filearchive/publications/1_2013guidelines.pdf. Accessed September 5, 2019
  29. ↵
    1. Kreitmeyr K,
    2. von Both U,
    3. Pecar A,
    4. Borde JP,
    5. Mikolajczyk R,
    6. Huebner J
    . Pediatric antibiotic stewardship: successful interventions to reduce broad-spectrum antibiotic use on general pediatric wards. Infection. 2017;45(4):493–504
    OpenUrl
  30. ↵
    1. Willis ZI,
    2. Gillon J,
    3. Xu M,
    4. Slaughter JC,
    5. Di Pentima MC
    . Reducing antimicrobial use in an academic pediatric institution: evaluation of the effectiveness of a prospective audit with real-time feedback. J Pediatric Infect Dis Soc. 2017;6(4):339–345
    OpenUrl
  31. ↵
    1. Klatte JM,
    2. Kopcza K,
    3. Knee A,
    4. Horton ER,
    5. Housman E,
    6. Fisher DJ
    . Implementation and impact of an antimicrobial stewardship program at a non-freestanding children’s hospital. J Pediatr Pharmacol Ther. 2018;23(2):84–91
    OpenUrl
  32. ↵
    1. Tamma PD,
    2. Cosgrove SE
    . Antimicrobial stewardship. Infect Dis Clin North Am. 2011;25(1):245–260
    OpenUrlCrossRefPubMed
  33. ↵
    1. Morris AM
    . Antimicrobial stewardship programs: appropriate measures and metrics to study their impact. Curr Treat Options Infect Dis. 2014;6(2):101–112
    OpenUrlCrossRefPubMed
  34. ↵
    1. Lee KR,
    2. Bagga B,
    3. Arnold SR
    . Reduction of broad-spectrum antimicrobial use in a tertiary children’s hospital post antimicrobial stewardship program guideline implementation. Pediatr Crit Care Med. 2016;17(3):187–193
    OpenUrl
  35. ↵
    1. Turner RB,
    2. Valcarlos E,
    3. Loeffler AM,
    4. Gilbert M,
    5. Chan D
    . Impact of an antimicrobial stewardship program on antibiotic use at a nonfreestanding children’s hospital. J Pediatric Infect Dis Soc. 2017;6(3):e36–e40
    OpenUrl
  • Copyright © 2019 by the American Academy of Pediatrics
View Abstract
PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Hospital Pediatrics: 9 (11)
Hospital Pediatrics
Vol. 9, Issue 11
1 Nov 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of a Prospective Audit and Feedback Antimicrobial Stewardship Program in Pediatric Units in Tertiary Care Teaching Hospital in Thailand
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Impact of a Prospective Audit and Feedback Antimicrobial Stewardship Program in Pediatric Units in Tertiary Care Teaching Hospital in Thailand
Sineenart Chautrakarn, Suvaporn Anugulruengkitt, Thanyawee Puthanakit, Thanapoom Rattananupong, Narin Hiransuthikul
Hospital Pediatrics Nov 2019, 9 (11) 851-858; DOI: 10.1542/hpeds.2019-0027

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Impact of a Prospective Audit and Feedback Antimicrobial Stewardship Program in Pediatric Units in Tertiary Care Teaching Hospital in Thailand
Sineenart Chautrakarn, Suvaporn Anugulruengkitt, Thanyawee Puthanakit, Thanapoom Rattananupong, Narin Hiransuthikul
Hospital Pediatrics Nov 2019, 9 (11) 851-858; DOI: 10.1542/hpeds.2019-0027
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Improving Pediatric Resident Safety Event Reporting Using Quality Improvement Methods
  • Quality Improvement Approach to Reducing Admission Hypothermia Among Preterm and Term Infants
  • Effects of a Poetry Intervention on Emotional Wellbeing in Hospitalized Pediatric Patients
Show more Research Articles

Similar Articles

Subjects

  • Infectious Disease
    • Infectious Disease
  • Child Care
    • Child Care
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Reviewer Guidelines
  • Submit My Manuscript
  • Open Access
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Subscribe
  • Contact Us
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • RSS Feeds
  • shopAAP
  • AAP.org
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
American Academy of Pediatrics

© 2021 American Academy of Pediatrics